PuSH - Publikationsserver des Helmholtz Zentrums München

Seiler, L.K.* ; Phung, N.L.* ; Nikolin, C.* ; Immenschuh, S.* ; Erck, C.* ; Kaufeld, J.* ; Haller, H.* ; Falk, C.S.* ; Jonczyk, R.* ; Lindner, P.* ; Thoms, S.* ; Siegl, J.* ; Mayer, G.* ; Feederle, R. ; Blume, C.A.*

An antibody-aptamer-hybrid lateral flow assay for detection of CXCL9 in antibody-mediated rejection after kidney transplantation.

Diagnostics 12:308 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
Chronic antibody-mediated rejection (AMR) is a key limiting factor for the clinical outcome of a kidney transplantation (Ktx), where early diagnosis and therapeutic intervention is needed. This study describes the identification of the biomarker CXC-motif chemokine ligand (CXCL) 9 as an indicator for AMR and presents a new aptamer-antibody-hybrid lateral flow assay (hybrid-LFA) for detection in urine. Biomarker evaluation included two independent cohorts of kidney transplant recipients (KTRs) from a protocol biopsy program and used subgroup comparisons according to BANFF-classifications. Plasma, urine and biopsy lysate samples were analyzed with a Luminex-based multiplex assay. The CXCL9-specific hybrid-LFA was developed based upon a specific rat antibody immobilized on a nitrocellulose-membrane and the coupling of a CXCL9-binding aptamer to gold nanoparticles. LFA performance was assessed according to receiver operating characteristic (ROC) analysis. Among 15 high-scored biomarkers according to a neural network analysis, significantly higher levels of CXCL9 were found in plasma and urine and biopsy lysates of KTRs with biopsyproven AMR. The newly developed hybrid-LFA reached a sensitivity and specificity of 71% and an AUC of 0.79 for CXCL9. This point-of-care-test (POCT) improves early diagnosis-making in AMR after Ktx, especially in KTRs with undetermined status of donor-specific HLA-antibodies.
Altmetric
Weitere Metriken?
[➜Einloggen]
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Korrespondenzautor
Schlagwörter Antibody ; Antibody-mediated Rejection (amr) ; Aptamer ; Aptamer-antibody-hybrid Lateral Flow Assay (hybrid-lfa) ; Biomarkers ; Cxcl9 (mig) ; Neural Net Analysis; Donor-specific Antibody; Non-hla Antibodies; Urinary Cxcl9; Ifn-gamma; Activation; Chemokines; Classification; Expression; Challenges; Induction
ISSN (print) / ISBN 2075-4418
e-ISSN 2075-4418
Zeitschrift Diagnostics
Quellenangaben Band: 12, Heft: 2, Seiten: , Artikelnummer: 308 Supplement: ,
Verlag MDPI
Verlagsort St Alban-anlage 66, Ch-4052 Basel, Switzerland
Nichtpatentliteratur Publikationen
Begutachtungsstatus Peer reviewed
Institut(e) CF Monoclonal Antibodies (CF-MAB)
Förderungen Central Innovation Program for Small and Medium Entrepreneurs of the Federal Ministry for Economic Affairs and Energy Germany
German Center for Infection Research
Deutsche Forschungsgemeinschaft